BioCentury
ARTICLE | Finance

X-ing out resistance

Public funding roundup 3Q16

October 6, 2016 7:00 AM UTC

Government, charity and academic organizations in the U.S. and U.K. are teaming up to bridge the translational valley of death for new products to battle antimicrobial resistance with Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a project that will invest $350 million over the next five years to help companies build up their pipelines and move new therapeutics, vaccines and devices toward the clinic.

The program has its roots in the National Strategy for Combating Antibiotic Resistant Bacteria, an initiative backed by President Obama two years ago, and is a vehicle to tackle several pieces of the National Action Plan to Combat Antibiotic-Resistant Bacteria released last year. ...